A Single Dose of the DENV-1 Candidate Vaccine rDEN1Δ30 Is Strongly Immunogenic and Induces Resistance to a Second Dose in a Randomized Trial

Spatial Evaluation and Modeling of Dengue Seroprevalence and Vector Density in Rio de Janeiro, Brazil

(2014) Nildimar Alves Honório et al.   PLoS Neglected Tropical Diseases

Development of sanofi pasteur tetravalent dengue vaccine

(2011) Bruno Guy et al.   Human vaccines & immunotherapeutics

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults

(2010) Wellington Sun et al.   Human vaccines & immunotherapeutics

A Novel Tetravalent Dengue Vaccine Is Well Tolerated and Immunogenic against All 4 Serotypes inFlavivirus‐Naive Adults

(2010) Dennis Morrison et al.   JOURNAL OF INFECTIOUS DISEASES

Recent progress on sanofi pasteur's dengue vaccine candidate

(2009) Jean Lang   JOURNAL OF CLINICAL VIROLOGY

Changing Patterns of Dengue Epidemiology and Implications for Clinical Management and Vaccines

(2009) Cameron P. Simmons et al.   PLOS MEDICINE

Global Spread and Persistence of Dengue

(2008) Jennifer L. Kyle et al.   Annual Review of Microbiology

Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4

(2008) Joseph E. Blaney et al.   VACCINE

Spatial and Temporal Clustering of Dengue Virus Transmission in Thai Villages

(2008) Mammen P Mammen et al.   PLOS MEDICINE